| Company/Division name | Raybow USA |
| Parent company | Raybow Pharmaceutical Co., Ltd |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 100 |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2021 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 15.8 |
| City reshored to: | Brevard |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | niche commercial API’s, pharmaceuticals |
| What domestic positive factors made reshoring more attractive? | Impact on domestic economy, Under-utilized capacity |
